胸部恶性肿瘤合并2019冠状病毒病患者的确切预后评估系统:TERAVOLT登记研究更新
基于TERAVOLT全球登记研究,纳入18个国家1491例胸部恶性肿瘤合并COVID-19患者,平均观察42天,全因病死率24.2%。通过聚类、快速后退逐步选择法和树模型从73个变量中识别出7个独立死亡决定因素,构建的列线图可将病死率风险分为8%至90%,模型AUC为0.78(95%CI 0.75-0.81)。
要点
- ECOG-PS差与COVID-19不良结局关联最强(OR=2.47,95%CI 1.87-3.26)。
- 中性粒细胞计数(OR=2.46,95%CI 1.76-3.44)和降钙素原(OR=2.37,95%CI 1.64-3.43)为独立死亡决定因素。
- 列线图可将COVID-19病死率风险分为8%至90%的区间。
核心结论
- 从73个变量中识别出7个主要死亡决定因素,ECOG-PS差与COVID-19不良结局关联最强。
- 该分析为临床医生提供了确切的预后评估系统,以帮助确定胸部恶性肿瘤合并COVID-19患者的死亡风险。
研究设计与样本
- 基于TERAVOLT全球登记研究(胸部恶性肿瘤国际COVID-19协作组)的数据分析。
- 截至2021年4月15日,纳入来自18个国家的1491例连续合格患者。
- 采用聚类方法、快速后退逐步选择法和树模型筛选并优化变量。
主要发现
- 平均观察期42天,报告361例事件,全因病死率为24.2%。
- 聚类过程筛选了13个聚类中的73个协变量,多变量logistic回归显示5个聚类与死亡显著相关。
- 快速后退逐步选择法识别出7个主要死亡决定因素:ECOG-PS(OR=2.47,95%CI 1.87-3.26)、中性粒细胞计数(OR=2.46,95%CI 1.76-3.44)、血清降钙素原(OR=2.37,95%CI 1.64-3.43)、肺炎发生(OR=1.95,95%CI 1.48-2.58)、C反应蛋白(OR=1.90,95%CI 1.43-2.51)、COVID-19诊断时肿瘤分期(OR=1.97,95%CI 1.46-2.66)和年龄(OR=1.71,95%CI 1.29-2.26)。
- 所选模型的ROC分析证实其诊断能力(AUC=0.78,95%CI 0.75-0.81)。
- 列线图可将COVID-19病死率分类为8%至90%的区间,树模型识别ECOG-PS、中性粒细胞计数和C反应蛋白为预后主要决定因素。
关键数值与推荐
- ECOG-PS:OR=2.47(95%CI 1.87-3.26)。
- 中性粒细胞计数:OR=2.46(95%CI 1.76-3.44)。
- 血清降钙素原:OR=2.37(95%CI 1.64-3.43)。
- 肺炎发生:OR=1.95(95%CI 1.48-2.58);C反应蛋白:OR=1.90(95%CI 1.43-2.51)。
- 肿瘤分期:OR=1.97(95%CI 1.46-2.66);年龄:OR=1.71(95%CI 1.29-2.26)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with thoracic malignancies are at increased risk for mortality from coronavirus disease 2019 (COVID-19), and a large number of intertwined prognostic variables have been identified so far. METHODS: Capitalizing data from the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry, a global study created with the aim of describing the impact of COVID-19 in patients with thoracic malignancies, we used a clustering approach, a fast-backward step-down selection procedure, and a tree-based model to screen and optimize a broad panel of demographics and clinical COVID-19 and cancer characteristics. RESULTS: As of April 15, 2021, a total of 1491 consecutive eligible patients from 18 countries were included in the analysis. With a mean observation period of 42 days, 361 events were reported with an all-cause case fatality rate of 24.2%. The clustering procedure screened 73 covariates in 13 clusters. A further multivariable logistic regression for the association between clusters and death was performed, resulting in five clusters significantly associated with the outcome. The fast-backward step-down selection procedure then identified the following seven major determinants of death: Eastern Cooperative Oncology Group-performance status (ECOG-PS) (OR = 2.47, 1.87-3.26), neutrophil count (OR = 2.46, 1.76-3.44), serum procalcitonin (OR = 2.37, 1.64-3.43), development of pneumonia (OR = 1.95, 1.48-2.58), C-reactive protein (OR = 1.90, 1.43-2.51), tumor stage at COVID-19 diagnosis (OR = 1.97, 1.46-2.66), and age (OR = 1.71, 1.29-2.26). The receiver operating characteristic analysis for death of the selected model confirmed its diagnostic ability (area under the receiver operating curve = 0.78, 95% confidence interval: 0.75-0.81). The nomogram was able to classify the COVID-19 mortality in an interval ranging from 8% to 90%, and the tree-based model recognized ECOG-PS, neutrophil count, and c-reactive protein as the major determinants of prognosis. CONCLUSIONS: From 73 variables analyzed, seven major determinants of death have been identified. Poor ECOG-PS was found to have the strongest association with poor outcome from COVID-19. With our analysis, we provide clinicians with a definitive prognostication system to help determine the risk of mortality for patients with thoracic malignancies and COVID-19.
引用
- Whisenant JG, Baena J, Cortellini A, et al. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. J Thorac Oncol. 2022. PMID: 35121086. doi:10.1016/j.jtho.2021.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。